AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00086060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation training
Description: Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
Study NCT00086060 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
Study NCT01979029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preserving the left colic artery
Description: The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
Study NCT04079153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular advancement Appliance
Description: Advances the mandible at desired range at a fixed vertical dimension
Study NCT03700437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet
Description: Chemo-immunotherapy + FMD (fast-mimicking diet)
Study NCT02110797 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: biological markers and evaluation of the mineral density at the lumber spine using DEXA
Study NCT03371901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy with BFR-LLST
Description: The criteria-based rehabilitation protocol for the patients with cartilage or meniscus repair may vary according to the surgical procedures.~Patients will attend 5 individual treatments, and a 6-week supervised group-based rehabilitation program with BFR-LLST (Blood Flow Restriction - Low Load Strength Training) twice a week at the rehabilitation centre. Patient will be instructed to perform BFR-LLST 5 times a week in total (twice supervised, 3 times at home).~During each BFR-LLST session, patients are encouraged to perform 4 sets of 30 repetitions, 15 repetitions, 15 repetitions, and 15 repetitions (or to fatigue in the final set), respectively.~The exercise intervention will adhere to TIDieR (template for intervention description and replication).
Study NCT03445819 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Group A: Surgical Treatment
Description: Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon
Study NCT03445819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group B: Conservative Treatment
Description: Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery.
Study NCT03561623 — intervention group
Intervention type: OTHER
Intervention: magnetic resonance (MR) Imaging
Description: MRI of spinal cord and brain
Study NCT03561623 — intervention group
Intervention type: OTHER
Intervention: quantitative muscle force assessment
Description: quantitative assessment of muscle force
Study NCT02670655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine/prilocaine (5%) application
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
Study NCT02670655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine/prilocaine (5%) application
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
Study NCT02670655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
Study NCT02670655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2940-nm Er:YAG AFL pretreatment
Description: After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
Study NCT02670655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAL application
Description: Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
Study NCT02670655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL application
Description: Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
Study NCT02670655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoresis application
Description: In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
Study NCT02670655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
Study NCT02670655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: irradiation with red light-emitting diode lamp
Description: After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
Study NCT02130505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone/rosiglitazone/placebo
Description: single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone/rosiglitazone/placebo
Description: single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone/pioglitazone/placebo
Description: single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosiglitazone/pioglitazone/placebo
Description: single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/pioglitazone/rosiglitazone
Description: single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
Study NCT01840774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose pain medication (Ketalar) and saline placebo
Study NCT01840774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose pain medication (Ketalar) and saline placebo
Study NCT04976842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OFA
Description: Anesthesiology technique based on Mulier protocol. Before induction, loading dose of dexmedetomidine 0,25mcg/kg (max 20mcg). Induction with dexmedetomidine 0,1mcg/kg, lidocaine 1mg/kg, ketamine 0,1mg/kg plus propofol 2mg/kg plus rocuronium1mg/kg IBW (if required). Maintenance with dexmedetomidine 0,1mcg/kg/h, lidocaine 1mg/kg/h, ketamine 0,1mg/kg/h and propofol infusion adjusted according to bispectral index indication ( BIS maintained 40-60). 15 minutes prior to end of surgery, the dose of drugs is reduced to dexmedetomidine 0,05mcg/kg/h, lidocaine 0,5mg/kg/h, ketamine 0,05mg/kg/h.
Study NCT04976842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OBA
Description: Total intravenous anesthesia with propofol for maintenance of anesthesia. Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).
Study NCT02535741 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon CR Total Knee System
Description: Primary total knee replacement
Study NCT03559712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative care, Telemental health
Description: Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
Study NCT05165615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump t:slim X2 with Control-IQ technology
Description: Usage of Insulin pump t:slim X2 with Control-IQ technology in previous users of AndroidAPS
Study NCT01990274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GeneXpert MTB/RIF assay
Description: Automated nucleic-acid amplification test (fully integrated) test for TB
Study NCT01990274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Smear microscopy
Description: Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
Study NCT01990274 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Smear microscopy
Description: Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
Study NCT00798369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
Study NCT00798369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
Study NCT00798369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
Study NCT02663635 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Safe'N'Sound
Study NCT04173026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provider-level intervention
Description: Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
Study NCT04173026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-level intervention
Description: 50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
Study NCT04475588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab IV infusion
Description: First dose of 1.6 mg/kg dose iv infusion, , investigator discretion to continue with 1.6 mg/kg dose every 2 weeks or 0.8 mg/kg weekly regimen up to 4 weeks.~BSC: similar to Arm B
Study NCT04475588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best supportive care (BSC)
Description: Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
Study NCT04475588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care (BSC)
Description: Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
Study NCT01483105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD Self-Hypnosis Training Program
Description: The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
Study NCT03899948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher Anxiety Program for Elementary Students
Description: TAPES consists of three core components: 1) training in evidenced-based anxiety reduction strategies that teachers will implement to identify and assist specific anxious students and classroom-wide strategies helpful to all students, 2) evidenced-based material for teachers to review with parents regarding how to reduce student anxiety at home, thus improving school-home communication and shared goals and 3) training in how to conduct 5 brief (30 minute) teacher-parent-student meetings to teach and practice the TAPES anxiety-reduction strategies.
Study NCT03899948 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teacher Anxiety Training
Description: The TAT is a 3-hour professional development training for teachers. Training focuses on recognizing the signs and symptoms related to child anxiety and utilizing classroom-wide strategies to help reduce anxiety in the classroom.
Study NCT03057938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben (FBB)
Description: All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
Study NCT03276689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: The patients will take duloxetine for 8 weeks.
Study NCT03276689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabaline
Description: The patients will take pregabaline for 8 weeks.
Study NCT03276689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will take placebo for 8 weeks.
Study NCT02431754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally
Study NCT02431754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02431754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpha1 Blocker
Description: Administered orally
Study NCT02431754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha1 Blocker
Description: Administered orally
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/pioglitazone/rosiglitazone
Description: single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone/placebo/rosiglitazone
Description: single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
Study NCT01088594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone/placebo/rosiglitazone
Description: single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
Study NCT00588822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be given as a 375 mg/m\^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
Study NCT02276872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral treprostinil
Study NCT01220479 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise training program
Description: Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive.
Study NCT01979029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: not preserving the left colic artery
Description: The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
Study NCT04162145 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active BRIDGE device placement
Description: The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
Study NCT04162145 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive BRIDGE device placement
Description: The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
Study NCT02855996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fathers in Action/Padres Activos (FA/PA) program
Description: The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
Study NCT01220479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive.
Study NCT06274541 — intervention group
Intervention type: GENETIC
Intervention: Somatic and Germline BRCA1/2 Testing
Description: Germline BRCA1/2 mutation testing will be undertaken by NGS using blood samples. Somatic BRCA1/2 mutation testing will be undertaken by NGS using tumour tissue.
Study NCT05505513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous Utah Slanted Electrode Arrays (pUSEAs)
Description: Microelectrode slanted arrays with a large number of electrodes will be surgically implanted into peripheral nerves of patients with limb amputations.